1887

Chapter 21 : Acquired Immunity: Acute Bacterial Infections

Author: Dennis W. Metzger1
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York 12208
Content Type: Monograph
Publication Year: 2011

Category: Immunology; Clinical Microbiology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Acquired Immunity: Acute Bacterial Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816872/9781555815141_Chap21-1.gif /docserver/preview/fulltext/10.1128/9781555816872/9781555815141_Chap21-2.gif

Abstract:

Acute bacterial infections continue to represent a major challenge to human health. The most effective approach for prevention of infection remains vaccination to induce protective acquired immunity. Acquired immunity to acute bacterial infections is the focus of this chapter. Bacterial toxins are well-known targets for vaccination to induce neutralizing antibody responses that prevent the symptoms of many acute bacterial infections. Most serum antibody is of the IgG isotype, which is capable of efficiently mediating opsonophagocytosis and complement fixation, as well as being transported across the placenta for protection of the developing fetus. is extensively utilized throughout the chapter as a model for acquired immunity to extracellular bacteria. In addition, and are discussed as models for "intracellular" pathogens that cause acute bacterial infections. The most common infections associated with IgA immune deficiency include recurrent bacterial ear infections, sinusitis, bronchitis, and pneumonia. IgD is expressed on the earliest mature B cell as an antigen co-receptor, together with IgM. Clearly, it would be preferable to contain infections in the respiratory tract (and other mucosal sites) before potentially serious inflammation develops. In addition to B cells, T cells certainly play an important role in acquired immunity to acute bacterial infections.

Citation: Metzger D. 2011. Acquired Immunity: Acute Bacterial Infections, p 269-277. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch21

Key Concept Ranking

Bacterial Outer Membrane Proteins
0.4214747
Infection and Immunity
0.4134452
Bacterial Proteins
0.40462807
0.4214747
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Acquired Immunity: Acute Bacterial Infections
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555816872.ch21-1,webId=/content/author/10.1128/9781555816872.ch21-1,properties={foaf_givenname=Dennis W., foaf_name=Dennis W. Metzger, foaf_surname=Metzger, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555816872.ch21-aff1]]}]]
Citation: Metzger D. 2011. Acquired Immunity: Acute Bacterial Infections, p 269-277. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch21
/content/10.1128/9781555816872.ch21.ch21fig01
FIGURE 1
Synergy between humoral and cell-mediated immunity. Antibodies in complex with target bacteria bind to Fc receptors on macrophages. However, for effective bacterial killing, the macrophages must be first activated by IFN-γ that is produced by bacteria-specific Th1 cells. In the absence of macrophage activation, antibody may actually enhance infection with bacteria that can replicate within macrophages, such as and Th17 cells also increase protection by recruitment of neutrophils and other innate effector cells to the infection site.
10.1128/9781555816872/f0273-01_thmb.gif
10.1128/9781555816872/f0273-01.gif
Image of FIGURE 1
FIGURE 1

Synergy between humoral and cell-mediated immunity. Antibodies in complex with target bacteria bind to Fc receptors on macrophages. However, for effective bacterial killing, the macrophages must be first activated by IFN-γ that is produced by bacteria-specific Th1 cells. In the absence of macrophage activation, antibody may actually enhance infection with bacteria that can replicate within macrophages, such as and Th17 cells also increase protection by recruitment of neutrophils and other innate effector cells to the infection site.

Citation: Metzger D. 2011. Acquired Immunity: Acute Bacterial Infections, p 269-277. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch21
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555816872.ch21.ch21fig02
FIGURE 2
Induction of IgG and IgA polysaccharide-specific antibodies by conjugate vaccines. A vaccine containing bacterial capsular polysaccharide (PS) covalently attached to a carrier protein (CRM) binds to PS-specific B cells through surface immunoglobulin receptors. The complexes are then internalized and the CRM carrier molecule is degraded into peptide fragments within B-cell lysosomes. These processed peptides are then bound to MHC class II molecules and presented to T cells. The T cells become activated and generate signals to the B cells to initiate immunoglobulin class switching. The result is production of PS-specific IgG and IgA antibodies as well as enhanced B-cell memory.
10.1128/9781555816872/f0274-01_thmb.gif
10.1128/9781555816872/f0274-01.gif
Image of FIGURE 2
FIGURE 2

Induction of IgG and IgA polysaccharide-specific antibodies by conjugate vaccines. A vaccine containing bacterial capsular polysaccharide (PS) covalently attached to a carrier protein (CRM) binds to PS-specific B cells through surface immunoglobulin receptors. The complexes are then internalized and the CRM carrier molecule is degraded into peptide fragments within B-cell lysosomes. These processed peptides are then bound to MHC class II molecules and presented to T cells. The T cells become activated and generate signals to the B cells to initiate immunoglobulin class switching. The result is production of PS-specific IgG and IgA antibodies as well as enhanced B-cell memory.

Citation: Metzger D. 2011. Acquired Immunity: Acute Bacterial Infections, p 269-277. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch21
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555816872.ch21.ch21fig03
FIGURE 3
A model for polymicrobial synergy between influenza virus and in the lung. During recovery from influenza, approximately 1 week after initial infection, virus-specific T cells are recruited into the pulmonary tract. These T cells secrete IFN-γ, which causes alveolar macrophages to express greater levels of MHC molecules, and also down regulates expression of certain scavenger receptors such as MARCO. The result is that adaptive immunity to the influenza virus is increased through more efficient antigen presentation. However, decreased expression of MARCO causes reduced recognition of nonopsonized pneumococci, leaving the host severely susceptible to secondary bacterial infection.
10.1128/9781555816872/f0275-01_thmb.gif
10.1128/9781555816872/f0275-01.gif
Image of FIGURE 3
FIGURE 3

A model for polymicrobial synergy between influenza virus and in the lung. During recovery from influenza, approximately 1 week after initial infection, virus-specific T cells are recruited into the pulmonary tract. These T cells secrete IFN-γ, which causes alveolar macrophages to express greater levels of MHC molecules, and also down regulates expression of certain scavenger receptors such as MARCO. The result is that adaptive immunity to the influenza virus is increased through more efficient antigen presentation. However, decreased expression of MARCO causes reduced recognition of nonopsonized pneumococci, leaving the host severely susceptible to secondary bacterial infection.

Citation: Metzger D. 2011. Acquired Immunity: Acute Bacterial Infections, p 269-277. In Kaufmann S, Rouse B, Sacks D (ed), The Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555816872.ch21
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555816872.ch21
1. Basset, A.,, C. M. Thompson,, S. K. Hollingshead,, D. E. Briles,, E. W. Ades,, M. Lipsitch, and, R. Malley. 2007. Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect. Immun. 75:5460–5464.
2. Burks, A. W., and, R. W. Steele. 1986. Selective IgA deficiency. Ann. Allergy 57:3–13.
3. Carneiro-Sampaio, M., and, A. Coutinho. 2007. Immunity to microbes: lessons from primary immunodeficiencies. Infect. Immun. 75:1545–1555.
4. Casadevall, A.,, E. Dadachova, and, L. A. Pirofski. 2004. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2:695–703.
5. Casadevall, A., and, L. A. Pirofski. 2006. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol. 91:1—44.
6. Cerutti, A. 2008. The regulation of IgA class switching. Nat. Rev. Immunol. 8:421–434.
7. Chen, K.,, W. Xu,, M. Wilson,, B. He,, N. W. Miller,, E. Bengten,, E. S. Edholm,, P. A. Santini,, P. Rath,, A. Chiu,, M. Cattalini,, J. Litzman,, B. Bussel,, B. Huang,, A. Meini,, K. Riesbeck,, C. Cunningham-Rundles,, A. Plebani, and, A. Cerutti. 2009. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat. Immunol. 10:889–898.
8. Conley, M. E.,, A. K. Dobbs,, D. M. Farmer,, S. Kilic,, K. Paris,, S. Grigoriadou,, E. Coustan-Smith,, V. Howard, and, D. Campana. 2009. Primary B cell immunodeficiencies: comparisons and contrasts. Annu. Rev. Immunol. 27:199–227.
9. Couch, R. B. 2004. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s Palsy. N. Engl. J. Med. 350:860–861.
10. Husband, A. J., and, J. L. Gowans. 1978. The origin and antigen-dependent distribution of IgA-containing cells in the intestine. J. Exp. Med. 148:1146–1160.
11. Janoff, E. N.,, C. Fasching,, J. M. Orenstein,, J. B. Rubins,, N. L. Opstad, and, A. P. Dalmasso. 1999. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J. Clin. Invest. 104:1139–1147.
12. Kirimanjeswara, G.,, J. W. Golden,, C. S. Bakshi, and, D. W. Metzger. 2007. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J. Immunol. 179:532–539.
13. Kirimanjeswara, G. S.,, Olmos S.,, Bakshi C.S., and, D. W. Metzger. 2008. Humoral and cell-mediated immunity to the intracellular pathogen, Francisella tularensis. Immunol. Rev. 225:244–255.
14. Klugman, K. P., and, S. A. Madhi. 2007. Pneumococcal vaccines and flu preparedness. Science 316:49–50.
15. Kuiken, T., and, J. K. Taubenberger. 2008. Pathology of human influenza revisited. Vaccine 26:D59-D66.
16. Kunkel, E. J., and, E. C. Butcher. 2003. Plasma-cell homing. Nat. Rev. Immunol. 3:822–829.
17. Kunkel, E. J.,, C. H. Kim,, N. H. Lazarus,, M. A. Vierra,, D. Soler,, E. P. Bowman, and, E. C. Butcher. 2003. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J. Clin. Invest. 111:1001–1010.
18. Liang, X. P.,, M. E. Lamm, and, J. G. Nedrud. 1989. Cholera toxin as a mucosal adjuvant for respiratory antibody responses in mice. Reg. Immunol. 2:244–248.
19. Louria, D. B.,, H. L. Blumenfeld,, J. T. Ellis,, E. D. Kilbourne, and, D. E. Rogers. 1959. Studies on influenza in the pandemic of 1957–1958. II. Pulmonary complications of influenza. J. Clin. Invest 38:213–265.
20. Lu, Y. J.,, J. Gross,, D. Bogaert,, A. Finn,, L. Bagrade,, Q. Zhang,, J. K. Kolls,, A. Srivastava,, A. Lundgren,, S. Forte,, C. M. Thompson,, K. F. Harney,, P. W. Anderson,, M. Lipsitch, and, R. Malley. 2008. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 4:e1000159.
21. Lynch, J. M.,, D. E. Briles, and, D. W. Metzger. 2003. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 71:4780–4788.
22. McCullers, J. A. 2006. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19:571–582.
23. McDermott, M. R., and, J. Bienenstock. 1979. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J. Immunol. 122:1892–1898.
24. Metzger, D. W. 2009. IL-12 as an adjuvant for the enhancement of protective humoral immunity. Expert Rev. Vaccines 8:515–518.
25. Metzger, D. W.,, C. S. Bakshi, and, G. Kirimanjeswara. 2007. Mucosal immunopathogenesis of Francisella tularensis. Ann. NY Acad. Sci. 1105:266–283.
26. Mitchison, N. A. 1971. The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur. J. Immunol. 1:18–27.
27. Mond, J. J.,, A. Lees, and, C. M. Snapper. 1995. T cell-independent antigens type 2. Annu. Rev. Immunol. 13:655–692.
28. Morens, D. M.,, J. K. Taubenberger, and, A. S. Fauci. 2008. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198:962–970.
29. Morteau, O.,, C. Gerard,, B. Lu,, S. Ghiran,, M. Rits,, Y. Fujiwara,, Y. Law,, K. Distelhorst,, E. M. Nielsen,, E. D. Hill,, R. Kwan,, N. H. Lazarus,, E. C. Butcher, and, E. Wilson. 2008. An indispensable role for the chemokine receptor CCR10 in IgA antibody-secreting cell accumulation. J. Immunol. 181:6309–6315.
30. Murthy, A. K.,, J. Sharma,, J. J. Coalson,, G. Zhong, and, B. P. Arulanandam. 2004. Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice. Cell. Immunol. 230:56–64.
31. Pan, J.,, E. J. Kunkel,, U. Gosslar,, N. Lazarus,, P. Langdon,, K. Broadwell,, M. A. Vierra,, M. C. Genovese,, E. C. Butcher, and, D. Soler. 2000. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J. Immunol. 165:2943–2949.
32. Parent, M. A.,, K. N. Berggren,, L. W. Kummer,, L. B. Wilhelm,, F. M. Szaba,, I. K. Mullarky, and, S. T. Smiley. 2005. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect. Immun. 73:7304–7310.
33. Rawool, D. B.,, C. Bitsaktsis,, Y. Li,, D. R. Gosselin,, Y. Lin,, N. V. Kurkure,, D. W. Metzger, and, E. J. Gosselin. 2008. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J. Immunol. 180:5548–5557.
34. Rudzik, R.,, R. L. Clancy,, D. Y. Perey,, R. P. Day, and, J. Bienenstock. 1975. Repopulation with IgA-containing cells of bronchial and intestinal lamina propria after transfer of homologous Peyer’s patch and bronchial lymphocytes. J. Immunol. 114:1599–1604.
35. Sabirov, A., and, D. W. Metzger. 2006. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine 24:5584–5592.
36. Schneerson, R.,, O. Barrera,, A. Sutton, and, J. B. Robbins. 1980. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361–376.
37. Siegrist, C. A., and, R. Aspinall. 2009. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9:185–194.
38. Smiley, S. T. 2008. Immune defense against pneumonic plague. Immunol. Rev. 225:256–271.
39. Steinitz, M.,, S. Tamir,, M. Ferne, and, A. Goldfarb. 1986. A protective human monoclonal IgA antibody produced in vitro: anti-pneumococcal antibody engendered by Epstein-Barr virus-immortalized cell line. Eur. J. Immunol. 16:187–193.
40. Stiver, H. G. 2004. The threat and prospects for control of an influenza pandemic. Expert Rev. Vaccines 3:35–42.
41. Sun, K.,, F. E. Johansen,, L. Eckmann, and, D. W. Metzger. 2004. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J. Immunol. 173:4576–4581.
42. Sun, K., and, D. W. Metzger. 2008. Inhibition of pulmonary antibacterial defense by interferon-γ during recovery from influenza infection. Nat. Med. 14:558–564.
43. Sun, K.,, S. L. Salmon,, S. A. Lotz, and, D. W. Metzger. 2007. Interleukin-12 promotes IFN-γ-dependent neutrophil recruitment in the lung and improves protection against respiratory S. pneumoniae infection. Infect. Immun. 75:1196–1202.
44. Trzcinski, K.,, C. M. Thompson,, A. Srivastava,, A. Basset,, R. Malley, and, M. Lipsitch. 2008. Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect. Immun. 76:2678–2684.
45. Way, S. S.,, A. C. Borczuk, and, M. B. Goldberg. 1999. Adaptive immune response to Shigella flexneri 2a cydC in immunocompetent mice and mice lacking immunoglobulin A. Infect. Immun. 67:2001–2004.
46. Weisz-Carrington, P.,, M. E. Roux,, M. McWilliams,, J. M. Phillips-Quagliata, and, M. E. Lamm. 1979. Organ and iso-type distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system. J. Immunol. 123:1705–1708.
47. Wilson-Welder, J. H.,, M. P. Torres,, M. J. Kipper,, S. K. Mallapragada,, M. J. Wannemuehler, and, B. Narasimhan. 2009. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 98:1278–1316.
48. Wolfe, D. N.,, G. S. Kirimanjeswara,, E. M. Goebel, and, E. T. Harvill. 2007. Comparative role of immunoglobulin A in protective immunity against the Bordetellae. Infect. Immun. 75:4416–4422.
49. Wu, H. Y., and, M. W. Russell. 1993. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 61:314–322.
50. Zhang, Z.,, T. B. Clarke, and, J. N. Weiser. 2009. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J. Clin. Invest. 119:1899–1909.

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error